•
CR
CRVO
CervoMed Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
61.44M
Volume
131.56K
52W High
$16.94
52W Low
$1.92
Open
$0.00
Prev Close
$6.99
Day Range
0.00 - 0.00
About CervoMed Inc. Common Stock
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Latest News
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
GlobeNewswire Inc.•Dec 4
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
GlobeNewswire Inc.•Dec 2
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
GlobeNewswire Inc.•Nov 24
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
GlobeNewswire Inc.•Oct 22
CervoMed to Present at the Emerging Growth Conference
GlobeNewswire Inc.•Oct 20
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
GlobeNewswire Inc.•Oct 2
CervoMed to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Sep 3
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
GlobeNewswire Inc.•Jul 28